The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer.
Richard S. Finn
Consultant or Advisory Role - Array BioPharma
Research Funding - Array BioPharma
Milind M. Javle
No relevant relationships to disclose
Benjamin R. Tan
Research Funding - Array BioPharma
Colin D. Weekes
No relevant relationships to disclose
Johanna C. Bendell
No relevant relationships to disclose
Amita Patnaik
Research Funding - Array BioPharma
Gazala Naaz Khan
No relevant relationships to disclose
Dan Laheru
No relevant relationships to disclose
Lisa Anderson
Employment or Leadership Position - Array BioPharma
Stock Ownership - Array BioPharma
Janna Lynn Christy-Bittel
Employment or Leadership Position - Array BioPharma
Stock Ownership - Array BioPharma
Emma Barrett
Employment or Leadership Position - Array BioPharma
Stock Ownership - Array BioPharma
Kari Guthrie
Employment or Leadership Position - Array BioPharma
Stock Ownership - Array BioPharma
Kevin S. Litwiler
Employment or Leadership Position - Array BioPharma
Stock Ownership - Array BioPharma
Tanios S. Bekaii-Saab
Consultant or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Genentech
Honoraria - Amgen; Genentech
Research Funding - Oncolytics Biotech; Pfizer